Patents by Inventor Robert Kendall Morrison

Robert Kendall Morrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies and related molecules that bind to PSCA proteins
    Patent number: 7595379
    Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: September 29, 2009
    Assignee: Agensys, Inc.
    Inventors: Jean Gudas, Aya Jakobovits, Xiao-Chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
  • Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer
    Patent number: 7592149
    Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: September 22, 2009
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20090214556
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: April 30, 2009
    Publication date: August 27, 2009
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-Chi Jia, Jean Gudas
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO PSCA PROTEINS
    Publication number: 20090202548
    Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
    Type: Application
    Filed: March 27, 2009
    Publication date: August 13, 2009
    Applicant: AGENSYS, INC.
    Inventors: Jean GUDAS, Aya Jakobovits, Xiao-Chi Jia, Robert Kendall Morrison, Pia M. Challita-Eid, Arthur B. Raitano
  • Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
    Patent number: 7563444
    Abstract: A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: July 21, 2009
    Assignee: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO PSCA PROTEINS
    Publication number: 20090181034
    Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
    Type: Application
    Filed: March 4, 2009
    Publication date: July 16, 2009
    Inventors: Jean GUDAS, Aya Jakobovits, Xiao-Chi Jia, Robert Kendall Morrison, Karen Jene Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 213P1F11 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20090181891
    Abstract: A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization.
    Type: Application
    Filed: January 21, 2009
    Publication date: July 16, 2009
    Applicant: AGENSYS, INC.
    Inventors: Pia M. CHALLITA-EID, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 24P4C12 PROTEINS
    Publication number: 20090175796
    Abstract: Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
    Type: Application
    Filed: September 5, 2008
    Publication date: July 9, 2009
    Inventors: Arthur B. RAITANO, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Steven B. Kanner, Pia M. Challita-Eid, Xiao-chi Jia, Jean Gudas, Aya Jakobovits
  • 238P1B2 protein
    Patent number: 7553814
    Abstract: A novel gene (designated 238P1B2) and its encoded protein, and variants thereof, are described wherein 238P1B2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 238P1B2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 238P1B2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 238P1B2 can be used in active or passive immunization.
    Type: Grant
    Filed: July 6, 2006
    Date of Patent: June 30, 2009
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Pia M. Challita-Eid, Mary Faris, Rene S. Hubert, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 125P5C8 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20090162850
    Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
    Type: Application
    Filed: September 22, 2008
    Publication date: June 25, 2009
    Applicant: AGENSYS, INC.
    Inventors: MARY FARIS, PIA M. CHALLITA-EID, RENE S. HUBERT, DANIEL E. H. AFAR, ARTHUR B. RAITANO, WANGMAO GE, ROBERT KENDALL MORRISON, KAREN JANE MEYRICK MORRISON, AYA JAKOBOVITS
  • NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 184P1E2 USEFUL IN TREATMENT AND DETECTION OF CANCER
    Publication number: 20090148854
    Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
    Type: Application
    Filed: January 21, 2009
    Publication date: June 11, 2009
    Applicant: AGENSYS, INC.
    Inventors: Pia M. CHALLITA-EID, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Antibodies and related molecules that bind to PSCA proteins
    Patent number: 7541442
    Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: June 2, 2009
    Assignee: Agensys, Inc.
    Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Pia M. Challita-Eid, Arthur B. Raitano
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 58P1D12 PROTEINS
    Publication number: 20090068098
    Abstract: Antibodies and molecules derived therefrom that bind to 58P1D12 protein and variants thereof, are described wherein 58P1D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 58P1D12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 58P1D12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 58P1D12 can be used in active or passive immunization.
    Type: Application
    Filed: August 20, 2008
    Publication date: March 12, 2009
    Inventors: Steven B. KANNER, Aya Jakobovits, Jean Gudas, Arthur B. Raitano, Robert Kendall Morrison, Pia M. Challita-Eid, Xiao-chi Jia
  • Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
    Patent number: 7488479
    Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: February 10, 2009
    Assignee: Agensys, Inc.
    Inventors: Mary Faris, Pia M. Challita-Eid, Rene S. Hubert, Daniel E. H. Afar, Arthur B. Raitano, Wangmao Ge, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Aya Jakobovits
  • ANTIBODIES AND RELATED MOLECULES THAT BIND TO 161P2F10B PROTEINS
    Publication number: 20090022663
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Application
    Filed: August 21, 2008
    Publication date: January 22, 2009
    Inventors: Aya JAKOBOVITS, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-Chi Jia, Jean Gudas
  • Biological products
    Patent number: 7452976
    Abstract: There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: November 18, 2008
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison
  • Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer
    Publication number: 20080280822
    Abstract: A novel gene (designated 161P5C5) and its encoded protein, and variants thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table 1. Consequently, 161P5C5 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P5C5 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P5C5 can be used in active or passive immunization.
    Type: Application
    Filed: May 26, 2006
    Publication date: November 13, 2008
    Applicant: Agensys, Inc.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer
    Publication number: 20080233598
    Abstract: A novel gene (designated 121P2A3) and its encoded protein, and variants thereof, are described wherein 121P2A3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P2A3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P2A3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P2A3 can be used in active or passive immunization.
    Type: Application
    Filed: February 6, 2007
    Publication date: September 25, 2008
    Applicant: AGENSYS, INC.
    Inventors: Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Steve Chappell Mitchell, Daniel E. H. Afar, Doulas Saffran, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
  • Antibodies and related molecules that bind to 161P2F10B proteins
    Patent number: 7427399
    Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: September 23, 2008
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Jean Gudas
  • Methods to inhibit growth of prostate cancer cells
    Patent number: 7361338
    Abstract: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: April 22, 2008
    Assignee: Agensys, Inc.
    Inventors: Aya Jakobovits, Mary Faris, Arthur B. Raitano, Robert Kendall Morrison, Douglas Saffran, Wangmao Ge, Pia M. Challita-Eid